Sign in →

Test Code BARBU Barbiturates Confirmation, Urine

Important Note

ASANTE order code is BACON

Epic/Beaker code is LAB5543

MEDICAL CONFRIMATION TESTING

Performing Laboratory

Mayo Medical Laboratories in Rochester

Reporting Name

Barbiturates Confirmation, U

Specimen Type

Urine


Specimen Required


Container/Tube: Plastic, 60-mL urine bottle

Specimen Volume: 20 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative.

Additional Information:

1. No specimen substitutions.

2. No STATS are accepted for this procedure.

3. For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order BARBX / Barbiturates Confirmation, Chain of Custody, Urine.

4. Additional drug panels and specific requests are available. Call Mayo Medical Laboratories at 800-533-1710 or 507-266-5700.

5. If urine creatinine is required or adulteration of the sample is suspected, the following test should be requested, ADULT / Adulterants Survey, Urine. For additional information, please refer to ADULT / Adulterants Survey, Urine.

6. Submitting less than 20 mL will compromise our ability to perform all necessary testing.


Reject Due To

Hemolysis

Mild OK; Gross OK

Lipemia

NA

Icterus

Mild OK; Gross OK

Other

NA

Specimen Stability Information

Specimen Type Temperature Time
Urine Refrigerated (preferred) 14 days
  Frozen  14 days
  Ambient  72 hours

Specimen Minimum Volume

5 mL

Day(s) and Time(s) Performed

Monday through Thursday, Sunday

Analytic Time

2 days

Reference Values

Negative

 

Cutoff concentrations:

BUTALBITAL BY GC-MS

<100 ng/mL

 

AMOBARBITAL BY GC-MS

<100 ng/mL

 

PENTOBARBITAL BY GC-MS

<100 ng/mL

 

SECOBARBITAL BY GC-MS

<100 ng/mL

 

PHENOBARBITAL BY GC-MS

<100 ng/mL

Useful For

Detecting drug abuse involving barbiturates such as amobarbital, butalbital, pentobarbital, phenobarbital, and secobarbital

Method Name

Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

80345

G0480 (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BARBU Barbiturates Confirmation, U In Process

 

Result ID Test Result Name Result LOINC Value
21442 Butalbital-by GC/MS 18385-5
20642 Amobarbital-by GC/MS 16239-6
20643 Pentobarbital-by GC/MS 16240-4
20644 Secobarbital-by GC/MS 16238-8
20645 Phenobarbital-by GC/MS 16241-2
20651 Barbiturates Interpretation 69050-3
20647 Chain of Custody No LOINC Needed

Clinical Information

Barbiturates represent a class of drugs that were originally introduced as sleep inducers. Butalbital is also used to control severe headaches. Mephobarbital and phenobarbital are frequently used to control major motor (grand mal) seizures. These drugs are commonly abused as "downers" to induce sleep after an amphetamine- or cocaine-induced "high."

Interpretation

The presence of a barbiturate in urine at >200 ng/mL indicates use of 1 of these drugs.

 

Most of the barbiturates are fast acting; their presence indicates use within the past 3 days.

 

Phenobarbital, commonly used to control epilepsy, has a very long half-life. The presence of phenobarbital in urine indicates that the patient has used the drug sometime within the past 30 days.

Cautions

No significant cautionary statements.

 

This test is very specific for these compounds.

 

For chain-of-custody information, see BARBX / Barbiturates Confirmation, Chain of Custody, Urine.

Clinical Reference

Baselt RC, Cravey RH: Disposition of Toxic Drugs and Chemicals in Man. Third edition. Chicago, IL, Year Book Medical Publishers, 1989

Method Description

Gas chromatography-mass spectrometry confirmation with quantitation.(Porter WH, Moyer TP: Clinical toxicology. In Tietz Textbook of Clinical Chemistry. Second edition. Edited by CA Burtis, ER Ashwood. Philadelphia, WB Saunders Company, 1994, pp 1162-1167)